%0 Journal Article
%T Intralesional Methotrexate Injection for the Treatment of Epithelial Crateriform Tumor.
%A Cho JH
%A Lee HM
%A Kim YJ
%A Kim DH
%A Ahn HH
%A Seo SH
%J Ann Dermatol
%V 36
%N 4
%D 2024 Aug
%M 39082656
%F 0.722
%R 10.5021/ad.23.135
%X <B>BACKGROUND: </B>Intralesional methotrexate injection (IL-MTX) is an appropriate strategy for treating epithelial crateriform tumors (ECTs) when surgical excision can result in functional or cosmetic defects; however, not all ECTs are responsive to this treatment.<BR><B>OBJECTIVE: </B>This study aimed to evaluate the effectiveness of IL-MTX for ECTs and to determine the differences in clinical response according to the pathological features.<BR><B>METHODS: </B>The medical records of patients treated with IL-MTX for their ECTs were retrospectively reviewed. Effectiveness was evaluated in terms of size reduction and flattening.<BR><B>RESULTS: </B>Twenty-five cases of ECTs with biopsy were included in this study. Eight cases of keratoacanthoma (KA) and 15 cases of squamous cell carcinoma (SCC) were identified, but 2 cases could not be clearly distinguished. Seventeen patients (68%) showed a response after injection, and response rate in KA and SCC were 75% (6/8) and 60% (9/15), respectively. Nine patients showed complete resolution with IL-MTX. Patients received 3 injections, and regression was observed in 7.56 weeks after the first injection. According to histopathological results, patients with KA and SCC received 2 and 3.33 injections, respectively, and complete resolution was observed after 7 and 7.67 weeks, respectively.<BR><B>CONCLUSIONS: </B>IL-MTX is safe and effective, and could be considered as a useful non-surgical treatment option for ECTs. Both KA and crateriform SCC showed good response; However, KA showed a better response.